news
Cancer-suppressing cells identified in pancreatic cancer
Cells containing Meflin play a role in restraining the progression of pancreatic cancer and could lead to new therapies against the disease.
List view / Grid view
Drug Development
Filter the results
news
3D tissue models of brain tumours created in brain-mimicking environment
A new platform has the potential to better understand what dictates the invasive behaviour of brain tumours.
news
New compound keeps cells alive and functioning in a healthy state
A world-first compound that can keep cells alive and functioning in a healthy state could be revolutionary for medical emergencies.
news
In vitro toxicology and toxicity testing market to exhibit CAGR of 9.3 percent
The worldwide market for in vitro toxicology and toxicity testing is predicted to be worth $12.7 billion by the end of the forecast period.
news
Novel CAR T-cell therapy for leukaemia and lymphoma
Scientists in the US have developed a promising new CAR T-cell therapy that targets the BAFF-R protein, which has demonstrated superior cancer destruction to existing FDA-approved CAR-T therapies.
news
Study reveals how to make pancreatic cancer chemotherapy more effective
Researchers have shown that blocking a particular enzyme causes chemotherapy to become more effective against pancreatic cancers in pre-clinical studies.
article
Therapeutic antibodies in cancer therapy
Monoclonal antibodies have shown great promise in the treatment of various cancers. This article discusses how therapeutic antibodies are produced and the various treatment strategies that are currently being adopted.
article
Hitting the target – utilising recombinant antibodies for viral research
Having worked in antibody research for over 20 years, Gary McLean has seen how the industry has progressed and understands the potential that antibodies have in the future of medicine. Nikki Withers hears how the focus has shifted from discovery to genetic sequence manipulation and how this can be applied…
article
Evaluation of therapeutic antibody discovery technologies
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
article
Expert view: Opportunities in flow cytometry
New therapies that direct the immune system to identify and destroy cancer cells, such as CAR-T and immune checkpoint inhibitors, have revolutionised cancer treatment.
news
New strategy developed to speed up drug discovery process
A new drug discovery strategy predicts the clinical actions of new compounds to promote desired clinical responses and avoid side effects.
news
Treatment for polycystic kidney disease shows promising results
A potential treatment for polycystic kidney disease has shown positive results in animal testing.
article
Expert view: Advancing antibody discovery with picodroplet technology
It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.
news
New biological targets could lead to therapies for drug-resistant cancers
A study on how Polycombs regulate cellular identity could lead to alternative treatments for patients with drug-resistant cancer.
article
Expert view: Clarification of cell cultures without centrifugation
Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.